Opicapone clinical trials
Also written BIA 9-1067 and Ongentys.
How each study uses opicapone is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- 24 Apr 2020 · ONGENTYS · NDA 212489 (FDA, Drugs@FDA)
- European Union
- 24 Jun 2016 · Ongentys · EMEA/H/C/002790 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
43 studies that test it; most in 2009 (10)
| Year | Studies |
|---|---|
| 2007 | 1 |
| 2008 | 6 |
| 2009 | 10 |
| 2010 | 3 |
| 2011 | 5 |
| 2013 | 1 |
| 2014 | 3 |
| 2016 | 1 |
| 2017 | 3 |
| 2018 | 2 |
| 2019 | 1 |
| 2021 | 5 |
| 2022 | 1 |
| 2024 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 39 · Other 4
Bial - Portela C S.A. (37) · Neuromed IRCCS (1) · University Hospital of Ferrara (1) · SK Chemicals Co., Ltd. (1) · Rabin Medical Center (1) · Neurocrine Biosciences (1) · Medical University of South Carolina (1)
Often tested with
Tested in the same studies.
Levodopa (3) · Carbidopa (2) · Benserazide, levodopa drug combination (1) · Repaglinide (1)
Studies
Open first, then newest update. How each study uses opicapone is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 43
- Early COMT Inhibition in PDCompletedNot applicableNeuromed IRCCSNCT07917546Written as Opicapone 50 mg
- OpiCapone Effect on Motor Fluctuations and pAiNCompletedPhase 4Bial - Portela C S.A.NCT04986982Written as Opicapone 50 mg
- OpicApone Sleep dISorderCompletedPhase 4Bial - Portela C S.A.NCT04986995Written as Opicapone
- eArly levoDopa With Opicapone in Parkinson's paTients wIth motOr fluctuatioNs.CompletedPhase 4Bial - Portela C S.A.NCT04990284Written as Opicapone
- Relative Bioavailability and Bioequivalence Of Different Formulations of Opicapone in Healthy VolunteersCompletedPhase 1Bial - Portela C S.A.NCT02305277Written as BIA 9-1067 (clinical micronized, CM)
- Early ParkinSon wIth L-DOPA/DDCI and OpicapoNe (EPSILON Study)CompletedPhase 3Bial - Portela C S.A.NCT04978597Written as Opicapone 50 mg
- Opicapone as Adjunctive Therapy to Levodopa-Carbidopa Intestinal Gel in Parkinson's DiseaseCompletedNot applicableUniversity Hospital of FerraraNCT06432309Written as Opicapone 50 mg
- AGE Levels in ER+ Metastatic Breast Cancer Patients Receiving Endocrine TherapyTerminatedPhase 1Medical University of South CarolinaNCT03092635Written as OPC
- A Study to Evaluate the add-on Efficacy and Safety of Opicapone 50 mg or an Extra Dose of L-DOPA 100 mg for the Treatment of Wearing-off in Patients With PDCompletedPhase 4SK Chemicals Co., Ltd.NCT04821687Written as Ongentys 50mg
- Relative Bioavailability and Bioequivalence of OpicaponeCompletedPhase 1Bial - Portela C S.A.NCT03820037Written as Ongentys
- Continuation Treatment Protocol for Patient Who Participated in the BIA 9-1067-302 Clinical TrialCompletedPhase 3Rabin Medical CenterNCT01851850Written as Opicapone
- Bioavailability and Bioequivalence Between Two Active Pharmaceutical Ingredient (API) Sources of Opicapone (OPC)CompletedPhase 1Bial - Portela C S.A.NCT04265027Written as 50 mg BIA 9 1067
- A Study of the Pharmacokinetics, Pharmacodynamics, and Safety of Opicapone in Subjects With Parkinson's Disease Taking Levodopa.CompletedPhase 1Neurocrine BiosciencesNCT03496870Written as Opicapone
- Bioavailability and Bioequivalence Study of Two Different Sources of OpicaponeCompletedPhase 1Bial - Portela C S.A.NCT03116295Written as Opicapone (OPC)
- Efficacy and Safety of Opicapone in Clinical PracticeCompletedPhase 4Bial - Portela C S.A.NCT02847442Written as BIA 9-1067
- Mass Balance Recovery, Metabolite Profile and Metabolite Identification of [14C]-BIA 9-1067CompletedPhase 1Bial - Portela C S.A.NCT03119194Written as [14C]-BIA 9-1067
- Effect of Food on OpicaponeCompletedPhase 1Bial - Portela C S.A.NCT03116308Written as Opicapone (OPC)
- The Effect of BIA 9-1067 at Steady-state on the Levodopa PharmacokineticsCompletedPhase 1Bial - Portela C S.A.NCT02170376Written as BIA 9-1067
- Pharmacokinetics of BIA 9-1067 in Healthy Japanese and Caucasian SubjectsCompletedPhase 1Bial - Portela C S.A.NCT01520987Written as BIA 9-1067
- Tolerability, Pharmacokinetics and Pharmacodynamics of BIA 9-1067CompletedPhase 1Bial - Portela C S.A.NCT02071810Written as BIA 9-1067
See all 43 studies that test opicapone →
Given beside what is tested · 3 — opicapone is usual care or a partner of the new treatment
- Multicentre Study in Four Parallel Groups of Parkinson's Disease (PD) PatientsCompletedPhase 2Bial - Portela C S.A.NCT01568047Written as BIA 9-1067
- Effect of Paracetamol on Opicapone Pharmacokinetics in Healthy VolunteersCompletedPhase 1Bial - Portela C S.A.NCT02305017Written as BIA 9-1067
- Effect of Opicapone at Steady State on Warfarin PharmacokineticsCompletedPhase 1Bial - Portela C S.A.NCT02305030Written as BIA 9-1067
What changed recently
From the registry's own updates since Oct 20, 2026.
Newly registered1
- Early COMT Inhibition in PDNov 4, 2026NCT07917546
Codes
What other systems call opicapone · ClinicalTrials.gg INT005622
- MeSH (NLM) C549349opicaponeConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) Y5929UIJ5NOPICAPONEConfirmed FDA, NLM, Wikidata
- RxNorm 2362167One source FDA
- Wikidata Q27088208opicaponeConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C170258OpicaponeOne source FDA
- DrugBank DB11632One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C549349 | opicapone | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | Y5929UIJ5N | OPICAPONE | Confirmed FDA, NLM, Wikidata |
| RxNorm | 2362167 | — | One source FDA |
| Wikidata | Q27088208 | opicapone | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C170258 | Opicapone | One source FDA |
| DrugBank | DB11632 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.